A PILOT STUDY TO EVALUATE NUCLEIC ACID AMPLIFICATION TESTS TO PREDICT TB RELAPSE

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 目的：本研究的目的是确定不同的核酸扩增和肉汤培养试验在治疗早期和治疗后阶段获得的效用，以预测随后的结核病复发。 将测量细菌负荷和MTB活力：在大肠杆菌中通过定量rRNA、定性（MTD Gen-Probe）rRNA、mRNA;在肉汤培养物中“至阳性时间”;在循环白细胞（“burry coat”标本）中通过MTB DNA。 研究设计：该研究设计是对两个多中心结核病治疗试验过程中获得的标本进行盲法回顾性评价。 这是CDC赞助的研究。 入选标准为（1）入组TBTC / USPHS试验23或24，以及（2）提供书面知情同意书。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. OBJECTIVE: The aim of this study is to determine the utility of different nucleic acid amplification and broth culture tests obtained early in treatment and in the post-treatment periods to predict subsequent relapse of tuberculosis. Bacillary burden and MTB viability will be measured: in sputa by quantitative rRNA, qualitative (MTD Gen-Probe) rRNA, mRNA; 'time to positivity' in broth cultures; and in circulating leukocytes ("burry coat" specimens) by MTB DNA. RESEARCH PLAN: The study design is a blinded retrospective evaluation of specimens obtained in the course of two multi-center TB treatment trials. This is a CDC sponsored study. Inclusion criteria are (1) enrollment in TBTC / USPHS Trials 23 or 24, and (2) provision of written informed consent.